Adaptimmune Therapeutics PLC ADR | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
EUR0.89 |
Market Cap |
EUR345.6 M |
Shares Outstanding |
104.45 M |
Public Float |
- |
Adaptimmune Therapeutics PLC ADR | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.03 |
Market Cap |
$387.49 M |
Shares Outstanding |
104.71 M |
Public Float |
86.21 M |
Address |
60 Jubilee Avenue Abingdon Oxfordshire OX14 4RX United Kingdom |
Employees | - |
Website | http://adaptimmune.com |
Updated | 07/08/2019 |
Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. |